Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • GMP Failures & Pharma Compliance
    • Common GMP Failures
    • GMP Documentation & Records Failures
    • Cleaning & Sanitation Failures in GMP Audits
    • HVAC, Environmental Monitoring & Cross-Contamination Risks
  • Toggle search form

Audit Comments on Poor Cleaning of Non-Product Areas

Posted on November 25, 2025November 24, 2025 By digi


Audit Comments on Poor Cleaning of Non-Product Areas

Step-by-Step Guide for Managing Audit Comments on Poor Cleaning of Non-Product Areas

In pharmaceutical manufacturing, maintaining an effective cleaning program across all facility areas is essential to ensure product quality and patient safety. While significant attention is often given to product-contact surfaces, the cleanliness of non-product areas—such as warehouses, hallways, and administrative spaces—plays a vital role in contamination control. This tutorial provides a comprehensive step-by-step guide to addressing and resolving audit comments related to poor cleaning practices in these areas. By following a structured approach centered on an effective cleaning checklist for non product contact areas, pharmaceutical professionals can mitigate risks, comply with regulatory expectations, and maintain robust Good Manufacturing Practice (GMP) standards.

1. Understanding the Importance of Cleaning Non-Product Contact Areas in Pharma Facilities

Non-product contact areas, including warehouses, corridors, and equipment storage rooms, can act as reservoirs for contaminants that may ultimately compromise product quality. Despite not directly contacting the product, dust, debris, and clutter in these zones can contribute to cross-contamination risks via airborne particulates, personnel movement, or equipment transfer.

Pharmaceutical regulators—including the FDA, EMA, and MHRA—emphasize in their GMP guidances the necessity for maintaining cleanliness beyond product-contact surfaces. For instance, 21 CFR Part 211 stipulates that all manufacturing areas must be kept clean to avoid contamination. Furthermore, PIC/S PE 009 and EU GMP Volume 4 also highlight environmental control requirements that encompass non-product zones.

Failure to maintain cleanliness in these supporting areas often leads to common audit findings described as “audit comments” during routine inspections. Reported issues typically include accumulation of warehouse dust, poor housekeeping leading to excessive clutter, and lack of compliance with documented cleaning procedures. Such comments can trigger CAPAs (Corrective and Preventive Actions), affecting operational efficiency and regulatory compliance status.

Also Read:  Why Non-Product Contact Area Cleaning Still Matters for GMP Compliance

2. Preparing and Implementing a Comprehensive Cleaning Checklist for Non Product Contact Areas

Designing an effective cleaning checklist for non product contact areas is foundational for mitigating audit comments related to poor cleaning. This checklist must be detailed, risk-based, and aligned with regulatory expectations to ensure comprehensive coverage of all relevant zones. The following steps provide a systematic approach for checklist development and utilization:

Step 2.1: Identify and Categorize Non-Product Areas

  • Map all non-product zones: Clearly delineate all areas such as corridors, warehouses, maintenance rooms, staff locker areas, waste disposal zones, and storage.
  • Risk stratification: Assess the potential contamination risk posed by each location based on proximity to product manufacturing, airflow patterns, and personnel traffic.
  • Classification criteria: Assign cleaning frequency and procedure categories accordingly—for example, daily cleaning in high-traffic corridors versus weekly cleaning in peripheral storage.

Step 2.2: Develop Specific Cleaning Tasks and Frequencies

  • Task detailing: Each checklist item should specify what to clean (e.g., floors, walls, racks, light fixtures), with defined cleaning methods and materials.
  • Frequency allocation: Assign cleaning schedules based on risk and area usage to optimize resource allocation without compromising hygiene standards.
  • Visual aids and instructions: Incorporate pictures or diagrams where necessary to clarify cleaning scope.

Step 2.3: Define Acceptance Criteria and Verification Methods

  • Visual inspection: Criteria for visual cleanliness, absence of visible dust, grime, or clutter.
  • Quantitative monitoring: Use of environmental monitoring (e.g., particulate counts) in critical adjacent areas if applicable.
  • Audit trail: Documentation of cleaning executed with signatures, dates, and corrective notes if deviations are detected.

Step 2.4: Train Personnel and Implement Routine Review

  • Training: Deliver comprehensive training to cleaning staff on checklist usage, product safety context, and regulatory expectations.
  • Periodic review: Schedule regular evaluations of checklist effectiveness, incorporating audit feedback and identifying opportunities for continuous improvement.

Following these steps ensures a robust and auditable cleaning program that anticipates common inspection findings, directly addressing audit comments with a preventive and compliant framework.

Also Read:  GMP Requirements for Status Labels and Tags in Warehouses

3. Responding to Audit Comments: Corrective Measures for Warehouse Dust and Clutter

When auditors identify issues such as residual warehouse dust accumulation or excessive clutter in non-product contact areas, the pharmaceutical manufacturer must respond effectively to prevent recurrence and demonstrate regulatory commitment. Addressing these audit comments involves the following structured actions:

Step 3.1: Immediate Containment and Cleaning

  • Initiate an expedited cleaning operation targeting the affected areas using the approved cleaning procedures and materials.
  • Remove or reorganize clutter to facilitate effective cleaning and improve accessibility for routine maintenance.
  • Ensure proper disposal of waste and obsolete materials following environmental and GMP guidelines.

Step 3.2: Root Cause Analysis (RCA)

  • Investigate the underlying causes contributing to dust accumulation or clutter development, such as:
    • Inadequate cleaning frequencies or incomplete coverage in cleaning checklists.
    • Poor training or supervision of cleaning personnel.
    • Lack of storage discipline or obsolescence management in warehouses.
    • Insufficient housekeeping SOPs or lack of accountability.
  • Document findings comprehensively to support targeted corrective actions.

Step 3.3: Corrective and Preventive Actions (CAPA)

  • Revise the cleaning checklist for non product contact areas to incorporate missing elements or to increase cleaning frequency where necessary.
  • Implement enhanced training programs emphasizing GMP contamination control principles.
  • Establish rigorous monitoring and supervision of housekeeping tasks.
  • Improve warehouse organization through 5S or lean methodologies to minimize clutter.
  • Schedule follow-up audits internally to verify sustained effectiveness.

Step 3.4: Documentation and Communication

  • Prepare a formal response to the auditor’s comments detailing actions taken and timelines for full remediation.
  • Incorporate lessons learned into Quality Management System documentation to facilitate continuous improvement.

By rigorously applying these corrective steps, organizations can convert negative audit observations into opportunities to strengthen contamination control systems and demonstrate proactive compliance with guidelines such as those in WHO GMP materials.

4. Sustaining Compliance: Best Practices for Ongoing Monitoring and Improvement

Maintaining GMP compliance related to non-product contact area cleanliness requires ongoing vigilance, embedded in the facility’s culture and operational processes. The following best practices are essential for sustaining improvements and avoiding recurring audit comments:

4.1 Regular Audits and Self-Inspections

  • Schedule frequent internal audits focusing on housekeeping, particularly in high-risk non-product contact areas.
  • Use audit findings to continuously refine cleaning protocols and personnel training.
Also Read:  GMP Requirements for Batch Manufacturing Records in Pharma Plants

4.2 Environmental Monitoring Integration

  • Where relevant, incorporate particulate and microbial environmental monitoring data to validate effectiveness of cleaning procedures.
  • Correlate monitoring trends with housekeeping performance metrics to identify emerging risks early.

4.3 Data-Driven Continuous Improvement

  • Establish KPIs related to cleaning performance, such as the number of dust-related deviations or clutter observations.
  • Use corrective action trends to identify systemic weaknesses and deploy targeted solutions.

4.4 Leveraging Technology and Automation

  • Consider adopting digital cleaning logs, barcode verification systems, or automated cleaning validation methods to enhance reliability and traceability.

Embedding these practices supports a sustainable contamination control program compliant with internationally recognized GMP standards such as ICH Q7 and PIC/S guidance. It also fosters an audit-ready environment, reducing the frequency and severity of negative audit comments.

5. Summary and Key Takeaways for Pharmaceutical Professionals

This step-by-step tutorial has highlighted critical aspects of managing audit comments related to poor cleaning in non-product contact areas within pharmaceutical manufacturing environments. Key points for professionals across Quality Assurance, Quality Control, Validation, and Regulatory Affairs include:

  • Non-product areas significantly impact overall contamination control and require dedicated cleaning programs aligned with regulatory GMP expectations.
  • An effective cleaning checklist for non product contact areas must be risk-based, comprehensive, clearly documented, and regularly reviewed.
  • Responding to audit comments on warehouse dust and clutter involves immediate remediation, root cause analysis, CAPA implementation, and enhanced training and supervision.
  • Sustained compliance is ensured through continuous monitoring, environmental controls, internal audits, and leveraging technology.
  • Documentation and communication of cleaning program robustness underpin successful inspections by authorities such as FDA, EMA, and MHRA.

By integrating these recommendations into daily operations, pharmaceutical sites in the US, UK, and EU can assure regulatory bodies and stakeholders of their commitment to excellence in contamination control and patient safety.

Non-Product Areas Tags:audit, cleaning, non product areas, pharmagmp

Post navigation

Previous Post: Common Deviations in Clean Hold Time Studies
Next Post: Designing SOPs for Cleaning Non-Product Contact Areas

Quick Guide

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog

Latest Posts

  • GMP-cGMP Regulations & Global Standards
    • FDA cGMP Regulations for Drugs & Biologics
    • cGMP Requirements for Pharmaceutical Manufacturers
    • ICH Q7 and API GMP Expectations
    • Global & ISO-Based GMP Standards
    • GMP for Medical Devices & Combination Products
    • GMP for Pharmacies & Hospital Pharmacy Settings
  • Applied GMP in Pharma Manufacturing & Operations
    • GMP for Pharmaceutical Drug Product Manufacturing
    • GMP for Biotech & Biologics Manufacturing
    • GMP Documentation
    • GMP Compliance
    • GMP for APIs & Bulk Drugs
    • GMP Training
  • Computer System Validation (CSV) & GxP Computerized Systems
    • CSV Fundamentals in Pharma & Biotech
    • FDA CSV Guidance & 21 CFR Part 11 Alignment
    • GAMP 5 & Risk-Based Validation Approaches
    • CSV in Pharmaceutical & GxP Industries (Use-Cases & System Types)
    • CSV Documentation
    • CSV for Regulated Equipment & Embedded Systems
  • Data Integrity & 21 CFR Part 11 Compliance
    • Data Integrity Principles in cGMP Environments
    • FDA Data Integrity Guidance & Expectations
    • 21 CFR Part 11 – Electronic Records & Signatures
    • Data Integrity in GxP Computerized Systems
    • Data Integrity Audits
  • Pharma GMP & Good Manufacturing Practice
    • FDA 483, Warning Letters & GMP Inspections
    • Data Integrity, ALCOA+ & Part 11 / Annex 11
    • Process Validation, CPV & Cleaning Validation
    • Contamination Control & Annex 1
    • PQS / QMS / Deviations / CAPA / OOS–OOT
    • Documentation, Batch Records & GDP
    • Sterility, Microbiology & Utilities
    • CSV, GAMP 5 & Automation
    • Dosage-Form–Specific GMP (Solids, Liquids, Sterile, Topicals)
    • Supply Chain, Warehousing, Cold Chain & GDP
Widget Image
  • Never Assign Batch Release Responsibilities to Non-QA Personnel in GMP

    Never Assign Batch Release Responsibilities… Read more

  • Manufacturing & Batch Control
    • GMP manufacturing process control
    • Batch Manufacturing record requirements
    • Master Batch record template for pharmaceuticals
    • In Process control checks in tablet manufacturing
    • Line clearance procedure before batch start
    • Batch reconciliation in pharmaceutical manufacturing
    • Yield reconciliation GMP guidelines
    • Segregation of different strength products GMP
    • GMP controls for high potency products
    • Cross Contamination prevention in manufacturing
    • Line clearance checklist for production
    • Batch documentation review before qa release
    • Process parameters control limits in pharma
    • Equipment changeover procedure GMP
    • Batch manufacturing deviation handling
    • GMP expectations for batch release
    • In Process sampling plan for tablets
    • Visual inspection of dosage forms GMP requirements
    • In Process checks for filled vials
    • Startup and Shutdown procedure for manufacturing line
    • GMP requirements for blending and mixing operations
    • Process Control strategy in pharmaceutical manufacturing
    • Uniformity of dosage units in process controls
    • GMP checklist for oral solid dosage manufacturing
    • Process Control
    • Batch Documentation
    • Master Batch Records
    • In-Process Controls
    • Line Clearance
    • Yield & Reconciliation
    • Segregation & Mix-Ups
    • High Potency Products
    • Cross Contamination Control
    • Line Clearance
    • Batch Review
    • Process Parameters
    • Equipment Changeover
    • Deviations
    • Batch Release
    • In-Process Sampling
    • Visual Inspection
    • In-Process Checks for Vials
    • Start-Up & Shutdown
    • Blending & Mixing
    • Control Strategy
    • Dosage Uniformity
    • Hold Time Studies
    • OSD GMP Checklist
  • Cleaning & Contamination Control
  • Warehouse & Material Handling
    • Warehouse GMP
    • Material Receipt
    • Sampling
    • Status Labelling
    • Storage Conditions
    • Rejected & Returned
    • Reconciliation
    • Controlled Drugs
    • Dispensing
    • FIFO & FEFO
    • Cold Chain
    • Segregation
    • Pest Control
    • Env Monitoring
    • Palletization
    • Damaged Containers
    • Stock Verification
    • Sampling & Weighing Areas
    • Issue to Production
    • Traceability
    • Printed Materials
    • Intermediates
    • Cleaning & Housekeeping
    • Status Tags
    • Warehouse Audit
  • QC Laboratory & Testing
    • Analytical Method Validation
    • Chromatography Systems
    • Dissolution Testing
    • Assay & CU
    • Impurity Profiling
    • Stability & QC
    • OOS Investigations
    • OOT Trending
    • Sample Management
    • Reference Standards
    • Equipment Calibration
    • Instrument Qualification
    • LIMS & Electronic Data
    • Data Integrity
    • Microbiology QC
    • Sterility & Endotoxin
    • Environmental Monitoring
    • QC Documentation
    • Results Review
    • Method Transfer
    • Forced Degradation
    • Compendial Methods
    • Cleaning Verification
    • QC Deviations & CAPA
    • QC Lab Audits
  • Manufacturing & In-Process Control
    • Batch Manufacturing Records
    • Batch Manufacturing Records
    • Line Clearance
    • In-Process Sampling & Testing
    • Yield & Reconciliation
    • Granulation Controls
    • Blending & Mixing
    • Tablet Compression Controls
    • Capsule Filling Controls
    • Coating Process Controls
    • Sterile & Aseptic Processing
    • Filtration & Sterile Filtration
    • Visual Inspection of Parenteral
    • Packaging & Labelling Controls
    • Rework & Reprocessing
    • Hold Time for Bulk & Intermediates
    • Manufacturing Deviations & CAPA
  • Documentation, Training & QMS
    • SOP & Documentation Control
    • Training & Competency Management
    • Change Control & QMS Lifecycle
    • Internal Audits & Self-Inspection
    • Quality Metrics, Risk & Management Review
  • Production SOPs
  • QC Laboratory SOPs
    • Sample Management
    • Analytical Methods
    • HPLC & Chromatography
    • OOS & OOT
    • Data Integrity
    • Documentation
    • Equipment
  • Warehouse & Materials SOPs
    • Material Receipt
    • Sampling
    • Storage
    • Dispensing
    • Rejected & Returned
    • Cold Chain
    • Stock Control
    • Printed Materials
    • Pest & Housekeeping
  • Cleaning & Sanitization SOPs
  • Equipment & Qualification SOPs
  • Documentation & Data Integrity SOPs
  • Deviation/OOS/CAPA SOPs
    • Deviation Management
    • Root Cause
    • CAPA
    • OOS/OOT
    • Complaints
    • Recall
  • Training & Competency SOPs
    • Training System
    • Role-Based Training
    • OJT
    • Refresher Training
    • Competency
  • QA & QMS Governance SOPs
    • Quality Manual
    • Management Review
    • Internal Audit
    • Risk Management
    • Vendors & Outsourcing
  • About Us
  • Privacy Policy & Disclaimer
  • Contact Us

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme